MedTrace Logo

Carbonic Anhydrase II Responses to Basketball-Specific High-Intensity Interval Training

NCT07377851 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-01-30

No results posted yet for this study

Summary

This study aims to examine whether erythrocyte carbonic anhydrase II can be used as a biological marker of metabolic adaptation to basketball-specific high-intensity interval training. Carbonic anhydrase II is an enzyme involved in acid-base balance and carbon dioxide transport, and it may reflect physiological adaptations to intense exercise.

Healthy basketball players participated in a structured high-intensity interval training program designed to reflect the physical demands of basketball. Blood samples and performance-related measurements were collected before and after the training period to evaluate changes in erythrocyte carbonic anhydrase II levels and related metabolic responses.

The findings of this study are expected to improve the understanding of exercise-induced metabolic adaptations and to explore the potential use of erythrocyte carbonic anhydrase II as a practical biomarker for monitoring training responses in basketball players.

Conditions

  • Metabolic Adaptation to High-Intensity Interval Training

Interventions

BEHAVIORAL

Basketball-Specific High-Intensity Interval Training

A structured basketball-specific high-intensity interval training program consisting of repeated bouts of intense exercise interspersed with short recovery periods, designed to induce metabolic adaptations.

Sponsors & Collaborators

  • Karamanoğlu Mehmetbey University

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-01-10
Completion
2026-01-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07377851 on ClinicalTrials.gov